Mechanisms responsible for the altered pharmacokinetics of bosentan: Analysis utilizing rats with bile duct ligation-induced liver dysfunction

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 6, 2009, Pages 326-333

  Horiuchi, Isao ^a   Mori, Yun I ^a   Taguchi, Masato ^a   Ichida, Fukiko ^a   Miyawaki, Toshio ^a   Hashimoto, Yukiya ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Bilirubin; Bosentan; Liver dysfunction; Pharmacokinetics; Taurocholic acid

Indexed keywords

BILIRUBIN; BOSENTAN; CYTOCHROME P450 2C; CYTOCHROME P450 2C6; CYTOCHROME P450 3A2; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A4; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B2; TAUROCHOLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFUSION RATE; LIVER CLEARANCE; LIVER DYSFUNCTION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; WISTAR RAT;

ANIMALS; BILE DUCTS; CYTOCHROME P-450 ENZYME SYSTEM; LIGATION; LIVER DISEASES; MALE; RATS; RATS, WISTAR; SULFONAMIDES;

EID: 70349952429     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.671     Document Type: Article

References (23)

1. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228-235.
2. Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 1999; 27: 810-815.
3. Dingemanse J, Van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43: 1089-1115.
4. Van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002; 53: 589-595. DOI: 10.1046/ j.1365-2125.2002.01608.x.
5. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304: 610-616.
6. Letschert K, Komatsu M, Hummel-Eisenbeiss J, Keppler D. Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2. J Pharmacol Exp Ther 2005; 313: 549-556. DOI: 10.1124/jpet.104.081224.
7. Treiber A, Schneiter R, Haüsler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007; 35: 1400-1407. DOI: 10.1124/dmd.106.013615.
8. Higashi T, Urai M, Taguchi M, Hashimoto Y. Mechanism responsible for the decreased hepatic NADPH generation rate in rats with bilateral ureter ligation-induced renal failure. Biol Pharm Bull 2005; 28: 1809-1812. DOI: 10.1248/bpb.28.1809.
9. Sasa H, Hashimoto Y, Shimizu T, Inui K. Hepatic extraction of tacrolimus in rats with experimental liver diseases. Biol Pharm Bull 1998; 21: 610-614.
10. Tahara K, Saigusa K, Kagawa Y, Taguchi M, Hashimoto Y. Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure. Drug Metab Pharmacokinet 2006; 21: 389-394. DOI: 10.2133/dmpk.21.389.
11. Treiber A, Schneiter R, Delahaye S, Clozel M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther 2004; 308: 1121-1129. DOI: 10.1124/jpet.103.061614.
12. Ishida K, Honda M, Shimizu T, Taguchi M, Hashimoto Y. Stereoselective metabolism of carvedilol by the beta-naphthoflavone-inducible enzyme in human intestinal epithelial Caco-2 cells. Biol Pharm Bull 2007; 30: 1930-1933. DOI: 10.1248/bpb.30.1930.
13. Aoki K, Nakajima M, Hoshi Y, et al. Effect of aminoguanidine on lipopolysaccharide-induced changes in rat liver transporters and transcription factors. Biol Pharm Bull 2008; 31: 412-420. DOI: 10.1248/bpb.31.412.
14. Souidi M, Gueguen Y, Linard C, et al. In vivo effects of chronic contamination with depleted uranium on CYP3A and associated nuclear receptors PXR and CAR in the rat. Toxicology 2005; 214: 113-122. DOI: 10.1016/j.tox.2005.06.006.
15. Hoen PA, Bijsterbosch MK, Van Berkel TJ, Vermeulen NP, Commandeur JN. Midazolam is a phenobarbital-like cytochrome p450 inducer in rats. J Pharmacol Exp Ther 2001 299: 921-927.
16. Okabe H, Mizukami A, Taguchi M, Aiba T, Yasuhara M, Hashimoto Y. The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction. J Pharm Pharmacol 2003; 55: 479-486. DOI: 10.1211/002235702982.
17. Tanabe H, Taira S, Taguchi M, Hashimoto Y. Pharmacokinetics and hepatic extraction of metoprolol in rats with glycerol-induced acute renal failure. Biol Pharm Bull 2007; 30: 552-555. DOI: 10.1248/ bpb.30.552.
18. Kobayashi K, Urashima K, Shimada N, Chiba K. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol 2002; 63: 889-896. DOI: 10.1016/S0006-2952(01)00843-7.
19. Hata S, Wang P, Eftychiou N, et al. Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake. Am J Physiol Gastrointest Liver Physiol 2003; 285: G829-G839. DOI: 10.1152/ajpgi.00352.2002.
20. Kouzuki H, Suzuki H, Stieger B, Meier PJ, Sugiyama Y. Characterization of the transport properties of organic anion transporting polypeptide 1 (oatp1) and Na(1)/taurocholate cotransporting polypeptide (Ntcp): comparative studies on the inhibitory effect of their possible substrates in hepatocytes and cDNA-transfected COS-7 cells. J Pharmacol Exp Ther 2000; 292: 505-511.
21. Kouzuki H, Suzuki H, Ito K, Ohasi R, Sugiyama Y. Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 1999; 288: 627-634.
22. Noé B, Hagenbuch B, Stieger B, Meier PJ. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 1997; 16: 10346-10350.
23. Cui Y, König J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001; 276: 9626-9630. DOI: 10.1074/ jbc.M004968200.